scholarly journals VLDL Is the Leading Actor in Lipid Abnormality in Patients With Diabetes and Obesity

2017 ◽  
Vol 7 (4) ◽  
pp. 101-102 ◽  
Author(s):  
Hidekatsu Yanai
Author(s):  
Elisabetta Rinaldi ◽  
Maria Grazia Zenti ◽  
Maddalena Trombetta ◽  
Giulia Ceradini ◽  
Anna Altomari ◽  
...  

2016 ◽  
Vol 2016 ◽  
pp. 1-9 ◽  
Author(s):  
Włodzimierz Łuczyński ◽  
Barbara Głowińska-Olszewska ◽  
Artur Bossowski

As the available therapies for diabetes and obesity are not effective enough, diabetologists and educators search for new methods to collaborate with patients in order to support their health behaviors. The aim of this review is to discuss perspectives for the development of new empowerment-type therapies in the treatment of diabetes/obesity. Empowerment is a process whereby patients gain the necessary knowledge to influence their own behavior to improve the quality of their lives. It is carried out in five stages: (1) identify the problem, (2) explain the feelings and meanings, (3) build a plan, (4) act, and (5) experience and assess the execution. Although many years have passed since the advent and popularization of the concept of empowerment, the area remains controversial, mainly with regard to the methodology of therapy. Some previous studies have confirmed the positive effect of empowerment on body weight, metabolic control, and quality of life of patients with type 2 diabetes; however, few studies have been conducted in patients with type 1 diabetes. There is still a need to confirm the effectiveness of empowerment in accordance with Evidence Based Medicine by performing long-term observational studies in a large group of patients. In future, empowerment may become part of the standard of care for patients with diabetes and/or obesity.


Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 2101-P
Author(s):  
LEE-SHING CHANG ◽  
SHERVIN MALMASI ◽  
NAOSHI HOSOMURA ◽  
HUABING ZHANG ◽  
CHRISTOPHER J. BROWN ◽  
...  

2020 ◽  
Author(s):  
Shiv Kumar Sarin ◽  
Ashok Choudhury ◽  
George K Lau ◽  
Ming-Hua Zheng ◽  
Dong Ji ◽  
...  

Abstract Background and Aims: COVID-19 is a dominant pulmonary disease, with multisystem involvement, depending upon co morbidities. Its profile in patients with pre-existing chronic liver disease (CLD) is largely unknown. We studied the liver injury patterns of SARS-Cov-2 in CLD patients, with or without cirrhosis. Methods: Data was collected from 13 Asian countries on patients with CLD, known or newly diagnosed, with confirmed COVID-19. Result: Altogether, 228 patients [185 CLD without cirrhosis and 43 with cirrhosis] were enrolled, with comorbidities in nearly 80%. Metabolism associated fatty liver disease (113, 61%) and viral etiology (26, 60%) were common. In CLD without cirrhosis, diabetes [57.7% vs 39.7%, OR=2.1(1.1-3.7), p=0.01] and in cirrhotics, obesity, [64.3% vs. 17.2%, OR=8.1(1.9-38.8), p=0.002) predisposed more to liver injury than those without these. Forty three percent of CLD without cirrhosis presented as acute liver injury and 20% cirrhotics presented with either acute-on-chronic liver failure [5(11.6%)] or acute decompensation [4(9%)]. Liver related complications increased (p<0.05) with stage of liver disease; a Child-Turcotte Pugh score of 9 or more at presentation predicted high mortality [AUROC-0.94, HR=19.2(95CI 2.3-163.3), p<0.001, sensitivity 85.7% and specificity 94.4%). In decompensated cirrhotics, the liver injury was progressive in 57% patients, with 43% mortality. Rising bilirubin and AST/ALT ratio predicted mortality among cirrhosis. Conclusions: SARS-Cov-2 infection causes significant liver injury in CLD patients, decompensating one fifth of cirrhosis, and worsening the clinical status of the already decompensated. The CLD patients with diabetes and obesity are more vulnerable and should be closely monitored.


Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 252-OR
Author(s):  
MARWA AL-BADRI ◽  
CARA L. KILROY ◽  
JACQUELINE I. SHAHAR ◽  
SHAHEEN TOMAH ◽  
HANNAH GARDNER ◽  
...  

2011 ◽  
Vol 2011 ◽  
pp. 1-8 ◽  
Author(s):  
Kazuo Eguchi

Diabetes mellitus and obesity are both related to the risk of cardiovascular disease and sudden death. In hypertensive guidelines, diabetes and obesity, especially abdominal obesity, are regarded as high-risk factors. Ambulatory blood pressure monitoring (ABPM) is an established method for the management of hypertension. However, ABPM is not a standard tool for the management of hypertension in diabetes and obesity. In this paper, recent data on the use of ABPM in diabetes and obesity will be discussed. In patients with diabetes, the ambulatory BP level has been shown to be better than clinic BP in predicting cardiovascular events. A riser pattern has been associated with increased risk of cardiovascular disease. White-coat hypertension and masked hypertension in diabetics constitute a moderate risk. A nondipping pattern is very common in obese hypertensive patients. In this paper, we will summarize the findings on the use of ABPM in patients with diabetes and obesity.


2014 ◽  
Vol 16 (4) ◽  
pp. 266-274 ◽  
Author(s):  
Michal Klysik ◽  
Samita Garg ◽  
Sajal Pokharel ◽  
Jeffery Meier ◽  
Nayana Patel ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document